Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting WEE1 to Overcome ARID1A Mutation-Driven Osimertinib Resistance in EGFR-Mutant Lung Cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Oct 2025

Fukuda Koji, Nanjo Shigeki, Takeuchi Shinji, Chakrabarti Turja, Brown Tyiesha, Dev Sahadevan Sharon Wesley, Arai Sachiko, Sato Shigeki, Kotani Hiroshi, Nishiyama Akihiro, Sakaguchi Hiroyuki, Ohtsubo Koushiro, Taniguchi Hiroaki, Blakely Collin M, Bivona Trever G, Yano Seiji

Abstract excerpt

INTRODUCTION: Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI), is commonly used as a first-line treatment for EGFR-mutant NSCLC. Nevertheless, despite its efficacy, resistance remains a major clinical challenge with unknown underlying mechanisms. This study aimed to investigate the mechanisms driving osimertinib resistance and identify therapeutic strategies. METHODS: Using a mouse model...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Cycle Proteins

Share to Drug Resistance, Neoplasm

Share to Indoles

Share to Protein Kinase Inhibitors

Share to Protein-Tyrosine Kinases

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 40518016
DOI: 10.1016/j.jtho.2025.06.007
PMCID: PMC13310150

Genes

ARID1A
EGFR
WEE1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting WEE1 to Overcome ARID1A Mutation-Driven Osimertinib Resistance in EGFR-Mutant Lung Cancer.PMID 40518016Read ↗

Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer.Semantic proximity Read ↗

A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinomaSemantic proximity Read ↗

Overcoming Osimertinib Resistance in Advanced Non-small Cell Lung Cancer.Semantic proximity Read ↗

Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiencySemantic proximity Read ↗

PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3β signaling pathway in EGFR-mutant non-small cell lung cancer.Semantic proximity Read ↗

3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib.Semantic proximity Read ↗

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer.Semantic proximity Read ↗

ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.Semantic proximity Read ↗

Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.Semantic proximity Read ↗

3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinibSemantic proximity Read ↗

Integrative multi-omics identifies AP-1 transcription factor as a targetable mediator of acquired osimertinib resistance in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.